Silo Pharma Announces EPO Intent To Grant Patent For Novel 5-HT4 Agonist Approach Targeting Stress Prevention And Resilience

Silo Pharma, Inc. Silo Pharma, Inc., a developmental-stage biopharmaceutical company working on advanced formulations and drug delivery technologies for both traditional therapeutics and psychedelic-based treatments, announced that the European Patent Office European Patent Office has issued a Rule 71(3) communication indicating its intention to grant a patent for a European application titled “Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress.” The application, filed under European Patent Application No. 20786878.7, is licensed exclusively to Silo Pharma from Columbia University Columbia University.

The approved claims focus on methods for preventing stress-induced fear, depressive-like behaviors, and related affective disorders through the use of specific serotonin 4 (5-HT4) receptor agonists. This approach is distinct from traditional treatments, as it aims to target biological pathways associated with stress resilience rather than simply managing symptoms after they appear. By emphasizing proactive intervention, these methods could represent a more forward-looking strategy in addressing chronic stress and stress-related mental health conditions.

Eric Weisblum Eric Weisblum, Chief Executive Officer of Silo Pharma, stated that this development marks an important milestone for the company. He emphasized that the patent strengthens Silo’s international intellectual property footprint and highlights the potential of the 5-HT4 program. According to him, shifting toward preventive treatment strategies could address a large and underserved market of individuals living with stress-related disorders, which continue to rise globally.

Once formally granted, the patent is expected to cover major European markets, enhancing Silo Pharma’s strategic position as it advances its pipeline of central nervous system therapies. The company is also assessing the option of Unitary Patent protection and looking into key national validations to broaden market reach and maximize long-term commercial value.

As interest grows worldwide in treatments for mental health and stress-associated conditions, Silo Pharma is working to build a portfolio focused on next-generation CNS therapeutics that use differentiated mechanisms of action. With programs like the 5-HT4 initiative, the company aims to contribute to innovative approaches that support better mental health outcomes in the years ahead.